⌕
Ultragenyx Pharmaceutical · RARE · Nasdaq
Tenet — · insufficient data
Compare
$16.70+5.03%At close
$16.70+0.80 (+5.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Ultragenyx Pharmaceutical (RARE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is RARE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Defense WorldNov 17, 2026 · 06:39 ET
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches

Ultragenyx Pharmaceutical (NASDAQ: RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Bi…

RARE +5.0% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 06:02 ET
Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript…

RARE +5.0% todayRead at source ↗
● Seeking AlphaNov 12, 2026 · 02:31 ET
Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold

I initiate coverage of Ultragenyx Pharmaceutical with a Hold rating and $18 price target, citing a credible valuation floor but limited near-term catalysts. Two major late-stage pipeline failures have reset investor sent…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireNov 11, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Ultragenyx to Participate at Investor Conferences in London

NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 03:30 ETCOMPANY'S OWN WORDS
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, to…

RARE +5.0% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 12:38 ETEARNINGS EXPECTED BY FEB 16
Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot

Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CR…

RARE +5.0% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 00:45 ETEARNINGS EXPECTED BY FEB 16
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CE…

RARE +5.0% todayRead at source ↗
● MarketBeatNov 3, 2026 · 21:14 ETEARNINGS EXPECTED BY FEB 16
What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call

Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 18:51 ETEARNINGS EXPECTED BY FEB 16
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 18:31 ETEARNINGS EXPECTED BY FEB 16
Compared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) unde…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireOct 27, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 16
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-r…

RARE +5.0% todayRead at source ↗
● PRNewsWireOct 27, 2026 · 16:00 ET
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in Ig…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchOct 27, 2026 · 11:06 ETEARNINGS EXPECTED BY FEB 16
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

RARE +5.0% todayRead at source ↗
● Defense WorldOct 20, 2026 · 04:22 ET
Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 7,066 Shares of Company Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report) CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, fo…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchOct 15, 2026 · 11:35 ET
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 11:31 ET
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireOct 14, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following the previously announc…

RARE +5.0% todayRead at source ↗
● Defense WorldOct 12, 2026 · 01:44 ET
Analyzing Atara Biotherapeutics (NASDAQ:ATRA) & Ultragenyx Pharmaceutical (NASDAQ:RARE)

Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two comp…

RARE +5.0% todayRead at source ↗
● Zacks Investment ResearchOct 8, 2026 · 11:50 ET
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.…

RARE +5.0% todayRead at source ↗
● Proactive InvestorsOct 7, 2026 · 12:49 ET
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awa…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireOct 7, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PR…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 16:54 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE).  Such investors are advised to co…

RARE +5.0% todayRead at source ↗
● GlobeNewsWireOct 2, 2026 · 02:00 ETCOMPANY'S OWN WORDS
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene…

RARE +5.0% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE).  Such investors are advised to contact…

RARE +5.0% todayRead at source ↗

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just RARE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.